Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

Talimogene laherparepvec (T-VEC) plus ipilimumab has demonstrated greater antitumor activity versus ipilimumab alone, without additional toxicity, in patients with advanced melanoma. Here, we report the 5-year outcomes from a randomized phase II study. These data provide the longest efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Chesney, Jason A, Puzanov, Igor, Collichio, Frances A, Singh, Parminder, Milhem, Mohammed M, Glaspy, John, Hamid, Omid, Ross, Merrick, Friedlander, Philip, Garbe, Claus, Logan, Theodore, Hauschild, Axel, Lebbé, Celeste, Joshi, Harshada, Snyder, Wendy, Mehnert, Janice M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163510/
https://www.ncbi.nlm.nih.gov/pubmed/37142291
http://dx.doi.org/10.1136/jitc-2022-006270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163510/
https://www.ncbi.nlm.nih.gov/pubmed/37142291
http://dx.doi.org/10.1136/jitc-2022-006270

Ejemplares similares